Evidence map›Paper›PMID 42221507›Full record

ArticleFrontiers in urology2026

Optimal artificial urine formulations for

Deok Hyun Han, Jae Hoon Chung

Abstract read
In one paragraph

Article in Frontiers in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deok Hyun HanDepartment of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jae Hoon ChungDepartment of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To develop and characterize standardized Materials and methods: Homemade AU models were formulated from a physiologic base composition and modified to create disease-specific lithogenic conditions. The CaOx model used sodium oxalate fixed at 80 mg/L with stepwise calcium chloride escalation to 600%. The UA model was tested at uric acid concentrations of 500-1000 mg/L under acidic pH. The bacterial infection model was tested as two independent live-bacterial arms preset at bulk pH 6.5 or 9.0 before immersion to capture urease-driven alkalinization and surface colonization, and a non-bacterial ammonia-alkalinized control was also evaluated. Stents of three commercial types were immersed for 48 h under CDC biofilm-reactor conditions, and surface deposition was quantified as weight change per unit length (mg/mm). Results: In the CaOx model, surface-associated weight gain increased with calcium concentration up to 200% (0.98 g/L) but declined at higher levels owing to competing bulk precipitation. The UA model produced minimal deposition, with maximal weight gain at 600 mg/L. In the bacterial infection assay, weight gain was numerically highest in the arm preset at bulk pH 6.5 before immersion and remained substantial in the arm preset at pH 9.0, whereas the non-bacterial alkalinization model resulted in negligible deposits. Conclusions: These stone type-specific AU models provide defined, lab-preparable lithogenic screening conditions. Within this 48-h reactor assay, CaCl

Indexed as

biofilmsin vitro techniquessaltsstentsurine

Identifiers

PMID42221507
PMCPMC13215919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.